PTO/SB/05 (08-0  Approved for use through 07/31/2006. OMB 0651-00  U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERI  U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERI  U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERI  U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERI  Attorney Docket No.  0119-CIP	E er.
Under the Paperwork Reduction Act of 1995, no persons are required to response to 1995. No. O119-CIP	-
UTILITY WANG, Bing	
PATENT APPLICATION Penzofuran Derivatives	72
TRANSMITTAL Title Express Mail Label No. EV 316424008 U.S. =	<b>66728</b>
express Mail Laber No.   Express Mail Laber No.	10

TRANSMITTAL	Title		EV 316426	10843	5. 50
[RANSIMIT IX-	27 CER 1.53(b)) Exp	ress Mail Label No.	EV 316426		Q
(Only for new nonprovisional applications under	NTS AD	DRESS TO:	Mail Stop Patent App Commissioner for P. P.O. Box 1450 Alexandria VA 2231	atento	222
Fee Transmittal Form (e.g., PTO/SB/1¹ (Submit an original and a duplicate for fee p Applicant claims small entity status. See 37 CFR 1.27.  Papelicant claims small entity status. See 37 CFR 1.27.  Papelicant claims small entity status. See 37 CFR 1.27.  Papelicant claims small entity status. See 37 CFR 1.27.  Papelicant claims small entity status. See 37 CFR 1.27.  Papelicant claims small entity status. See 37 CFR 1.27.  Papelicant and papelication (Total Page (presence to sequence listing, a table, or a computer program listing appendix. Background of the Invention. Brief Summary of the Invention. Brief Description of the Drawings (if filed Description.)  Patalled Description. Claim(s). Abstract of the Disclosure.  Drawing(s) (35 U.S.C. 113) [Total 5. Oath or Declaration (Total 2. Newly executed (original or copy (for continuation/divisional with 1.5 (Signed statement attached deletiname in the prior application, see 1.63(d)(2) and 1.33(b).  Application Data Sheet. See 37 (1.2)	7) 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7.	Computer Property Nucleotide and/or (if applicable, all net a. Compute b. Specific i. Compute b. Specific ii. Statement ACCOMP/  9. Assignment 37 CFR 3 (when the English Tour 12. Information Statement 14. Return	D-R in duplicate, langram (Appendix) Amino Acid Sequencesary) er Readable Form (Cation Sequence List D-ROM or CD-R (2) Paper Inents verifying identify ANYING APPLIC Int Papers (cover she 173(b) Statement Int (IDS)/PTO-1449	ge table or ce Submission CRF) ting on: copies); or ty of above content of above content (if applicable citat (if applicable (	opies ARTS  ant(s)) or of er of es of IDS ions  122 TO/SB/35
18. If a CONTINUING APPLICATION, che specification following the title, or in an Application following the title, or in an Application information:  Prior application information:  For CONTINUATION OF DIVISIONAL APPS of 5b, is considered a part of the disclosure of the incorporation can only be relied upon we	continua cominer Deborah LAMBKIN	ation-in-part (CIP)	Art Unit: 1626	leclaration is s	and under Box
The incorporation games	19. CORREST OF	NDENCE ADDRES	OR Corresp	ondence add	ress below
Customer Number:	32004				
Name Gloria PFISTER GALILEO PHARMACEU	TICALS, INC.				
Address GALILEO PHARMACES 5301 Patrick Henry Drive	)	State CA		Zip Code	95054
City Santa Clara		Telephone 408-65	4-5830x237	Fax	408-654-5831
Country USA		Registration No.		15,642 Date 0/1	7/2003
Name (Print/Type)   Gloria PFISTER		· ·		ייחו שומנו	7/2003

This collection of information is required by 3 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, uspect of the uspect of the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent of the uspect of

Complete if Known

Approved for use through 07/31/2006. OMB 0651-0059

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

				•		
FEE IRANSMIIIA	L.	Appli	cation Number			
for FY 2003	į	Filing Date		09/17/2003		
		First	Named Invento	wANG, Bing		
Effective 01/01/2003. Patent fees are subject to annual revision.		Exam	niner Name			
Applicant claims small entity status. See 37 CFR 1.27		Art U	nit			
TOTAL AMOUNT OF PAYMENT (\$) 759.00		Attorr	ney Docket No.	0119-CIP		
METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
Check Credit card Money Other None	3. ADDITIONAL FEES Large Entity , Small Entity					
Deposit Account:	Fee		Fee Fee	Fac Description		
Deposit Account 50-2247	Cod		Code (\$)	Fee Description	Fee Paid	
Number	1051	130	2051 65 Su	urcharge - late filing fee or oath		
Deposit Account Galileo Pharmaceuticals	1052	50		urcharge - late provisional filing fee or over sheet		
Name The Director is authorized to: (check all that apply)	1053	130		on-English specification		
Charge fee(s) indicated below Credit any overpayments	1812	2,520	1812 2,520 Fo	or filing a request for ex parte reexamination		
Charge any additional fee(s) during the pendency of this application	1804	920*		equesting publication of SIR prior to xaminer action		
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1805	1,840*		equesting publication of SIR after xaminer action		
FEE CALCULATION	1251	110	2251 55 Ex	xtension for reply within first month		
1. BASIC FILING FEE	1252	410	2252 205 E	xtension for reply within second month		
Large Entity Small Entity	1253	930	2253 465 E	xtension for reply within third month		
Fee Fee Fee Fee Fee Paid Code (\$) Code (\$)	1254	1,450	2254 725 E	xtension for reply within fourth month		
1001 750 2001 375 Utility filing fee 375.00	1255	1,970	2255 985 E	xtension for reply within fifth month		
1002 330 2002 165 Design filing fee	1401	320	2401 160 N	lotice of Appeal		
1003 520 2003 260 Plant filing fee	1402	320	2402 160 Fi	iling a brief in support of an appeal		
1004 750 2004 375 Reissue filing fee	1403	280	2403 140 Re	equest for oral hearing		
1005 160 2005 80 Provisional filing fee	1451	1,510	1451 1,510 Pe	etition to institute a public use proceeding		
SUBTOTAL (1) (\$) 375.00	1452	110	2452 55 Pe	etition to revive - unavoidable		
	1453	1,300	2453 650 P	etition to revive - unintentional		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,300	2501 650 U	Itility issue fee (or reissue)		
Extra Claims below Fee Paid  Total Claims 44 -20** = 24 x 9 = 216	1502		1	esign issue fee		
Independent	1503		1	Plant issue fee		
Claims Multiple Dependent X 42 = 168	1460	130	1460 130 P	Petitions to the Commissioner		
	1807	50	1807 50 P	Processing fee under 37 CFR 1.17(q)		
Large Entity   Small Entity Fee Fee Fee Fee Fee Description	1806	180		ubmission of Information Disclosure Stmt		
Code (\$) Code (\$)	8021	40	8021 40 Re	ecording each patent assignment per		

**or number previ	iously paid, if greater; For Reissues, see above	*Reduced by Basic Fil	ing Fee Paid	SUBTOTAL	_ (3) (\$)	
SUBMITTED BY				(Complete	(if applicable))	
Name (Print/Type)	Gloria Pfister	Registration No. (Attorney/Agent)	45,642	Telephone	408-654-5830	
Signature	S. P. Slev	•		Date	9/17/2003	

1809

1810

1801

1802

750

750

750

900

Other fee (specify)

2809

2810

2801

1802

property (times number of properties)

375 Request for Continued Examination (RCE)

375 Filing a submission after final rejection (37 CFR 1.129(a))

375 For each additional invention to be

examined (37 CFR 1.129(b))

900 Request for expedited examination

of a design application

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1202

1201

1203 280

1204

1205

18

84

84

18

2202

2201

2203 140

2204

2205

9

42

42

SUBTOTAL (2)

Claims in excess of 20

over original patent

and over original patent

Independent claims in excess of 3

\*\* Reissue independent claims

\*\* Reissue claims in excess of 20

(\$) 384.00

Multiple dependent claim, if not paid